AzurRx BioPharma is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Co. is focused on developing its drug product candidate, MS1819, a yeast derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Co.'s b-lactamase program focuses on products with an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea by resistant bacterial strains induced by parenteral administration of several antibiotic classes. Co.'s compounds in pre-clinical development include: AZX1101 and AZX1103.
|
Free AZRX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.50 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |